| Literature DB >> 23208465 |
Janaína A Túrmina1, Emerson Carraro, Mário A Alves da Cunha, Robert F H Dekker, Aneli M Barbosa, Fábio Seidel Dos Santos, Luiz A Silva, Carlos R M Malfatti.
Abstract
Studies evaluating the toxicity caused by fungal exopolysaccharides of the β-(1-->6)-D-glucan type are rare. In this study, the toxicological effects of sub-chronic treatments with lasiodiplodan (β-(1-->6)-D-glucan from Lasiodiplodia theobromae MMPI) were evaluated in mice through the assessment of biochemical, hematological, and histopathological alterations. Thirty-two mice (16 male, 16 female) were used in this study divided in two groups; one group received lasiodiplodan (50 mg/kg body weight) daily for 28 days via gavage, and another (control group) received saline during the same period. Blood samples were collected via cardiac puncture for hematological and biochemical analyses. Liver, heart, kidney, and spleen were collected for histopathological analysis. Statistical analysis was performed through one-way analysis of variance and only p < 0.05 F-values were presented. Significant reduction in blood glucose in the male group (35%; p < 0.01), transaminases activity in both sexes (AST and ALT; ~35%; p < 0.05), and urea (20%; p < 0.01) in the female group was observed with the lasiodiplodan treatment. The results showed that sub-chronic treatments with lasiodiplodan did not generate hematological and histopathological alterations leading to signs of toxicity in healthy mice, independent of gender.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23208465 PMCID: PMC6268985 DOI: 10.3390/molecules171214298
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Levels of blood glucose in mice exposed to sub-chronic treatment with lasiodiplodan. (A) male and (B) female groups. (*) Values based on p < 0.05.
Figure 2Hepatotoxicity markers in male mice submitted to sub-chronic treatment with lasiodiplodan. Specific transaminases (A) ALT and (B) AST; (C) creatinine, and urea (D). (*) Values based on p < 0.05.
Figure 3Hepatotoxicity markers in female mice submitted to sub-chronic treatment with lasiodiplodan. Specific transaminases (A) ALT and (B) AST; (C) creatinine, and urea (D). (*) Values based on p < 0.05.
Blood lipid profile of male and female mice groups after a 28-day treatment with lasiodiplodan by gavage.
| Treatment group a | Cholesterol | HDL b | LDL c | VLDL d | Triacylglycerol |
|---|---|---|---|---|---|
| Control | 143 ± 14.2 | 37 ± 3.9 | 70 ± 14.0 | 36 ± 12.0 | 178 ± 61.0 |
| Lasiodiplodan | 133 ± 17.2 | 36 ± 9.0 | 61 ± 14.1 | 36 ± 10.0 | 180 ± 50.0 |
| Control | 100 ± 8.17 | 26 ± 4.8 | 42 ± 16.6 | 32 ± 12.4 | 161 ± 19.0 |
| Lasiodiplodan | 91 ± 17.11 | 20 ± 6.6 | 38 ± 16.7 | 33 ± 8.5 | 164 ± 64.6 |
a n = 8; Cholesterols of: b high-density lipoprotein; c low-density lipoprotein; d very low-density lipoprotein (Triglycerides/5).
Hematological parameters of male and female mice groups after a 28-day treatment with lasiodiplodan by gavage.
| Leukogram | Control | Lasiodiplodan | ||
|---|---|---|---|---|
| Males | Females | Males | Females | |
| Total leukocytes (mm3) | 4.30 ± 0.20 | 4.00 ± 0.31 | 4.20 ± 0.12 | 4.10 ± 0.67 |
| Neutrophils (%) | 25.00 ± 1.58 | 25.50 ± 1.50 | 21.00 ± 2.21 | 21.87 ± 3.32 |
| Basophils (%) | 0.62 ± 0.18 | 1.12 ± 0.22 | 1.00 ± 0.18 | 1.42 ± 0.20 |
| Lymphocytes (%) | 71.12 ± 2.01 | 72.12 ± 2.30 | 75.50 ± 2.73 | 75.12 ± 3.18 |
| Monocytes (%) | 2.85 ± 0.91 | 2.95 ± 0.85 | 1.97 ± 0.45 | 3.00 ± 0.46 |
| Eosinophils (%) | 0.37 ± 0.18 | 0.75 ± 0.17 | 0.12 ± 0.08 | 0.12 ± 0.08 |
a n = 8.
Figure 4Histological tissue sections from male mice (100×). (A) kidney from the control group; (B) kidney from the lasiodiplodan-treated group; (C) spleen from the control group; (D) spleen from the lasiodiplodan-treated group; (E) heart from the control group; (F) heart from the lasiodiplodan-treated group; (G) hepatic tissue from the control group; and (H) hepatic tissue from the lasiodiplodan-treated group. Scale bar 25 micron.
Figure 5Histological tissue sections from female mice (100×). (A) kidney from the control group; (B) kidney from the lasiodiplodan-treated group; (C) spleen from the control group; (D) spleen from the lasiodiplodan-treated group; (E) heart from the control group; (F) heart from the lasiodiplodan-treated group; (G) hepatic tissue from the control group; and (H) hepatic tissue from the lasiodiplodan-treated group. Scale bar 25 micron.